Advanced Oncotherapy (AVO)

 

AVO Share PerformanceMore

52 week high120.000 19/10/16
52 week low9.525 19/07/17
52 week change -95.500 (-82.68%)
4 week volume3,216,925 24/08/17

Media for (AVO)

Presenter: Nicolas Serandour
05/09/2017

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Advanced Oncotherapy - Technological update

Technological update

RNS Number: 6608P Advanced Oncotherapy PLC 04 September 2017 ADVANCED ONCOTHERAPY PLC ("Advanced Oncotherapy" or the "Company") Technological update Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it remains on schedule with the development of the first L...

Advance Oncotherapy - Interview with Gabriel Urwitz

Director Deals - Advanced Oncotherapy PLC (AVO)

Dr Enrico Vanni, Non Executive Director, bought 100,000 shares in the company on the 31st July 2017 at a price of 17.75p. T...

Director Dealing

RNS Number: 6440M Advanced Oncotherapy PLC 01 August 2017 ADVANCED ONCOTHERAPY PLC ("Advanced Oncotherapy" or the "Company") Director Dealing Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday Dr Enrico Vanni, Non-Executive Director of the Com...

Technological milestones update - CCL units

RNS Number: 5067M Advanced Oncotherapy PLC 31 July 2017 ADVANCED ONCOTHERAPY PLC ("Advanced Oncotherapy" or the "Company") Technological milestones update - CCL units Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces the completion of a further technological mil...

Result of AGM

RNS Number: 5467L Advanced Oncotherapy PLC 19 July 2017 ADVANCED ONCOTHERAPY PLC ("Advanced Oncotherapy" or the "Company") Result of AGM Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that at the Annual General Meeting held earlier today, all resolutions were ...

Financing facility by significant shareholders

RNS Number: 4877L Advanced Oncotherapy PLC 19 July 2017 ADVANCED ONCOTHERAPY PLC ("Advanced Oncotherapy" or the "Company") Financing Facility provided by significant shareholders Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that a consortium formed by AB ...

Fundamental DataMore

EPS-17.01
Dividend yield0 %

Equity Research (AVO)

hardman & co
Advanced Oncotherapy Plc
15/03/2017
AVO is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world renowned CERN. The company is entering an exciting stage...
Advanced Oncotherapy Plc
27/02/2017
PowerHouse Energy Group (PHE.L) 1p £8.94m PowerHouse has agreed with University of Chester to deploy its G3-UHt unit (ultra-high temperature demonstration gasification system)  at its Thornton...
hardman & co
Advanced Oncotherapy Plc
02/11/2016
AVO is focused on delivering a more affordable, novel proton-based radiotherapy system, based on a technology originally developed and tested at the world renowned CERN. Planning Permission for its...

Latest discussion posts More

  • Progress perhaps ??

    When should we expect to receive the next morsel ??
    31-Aug-2017
    Dubliner2
  • Interesting RNS

    So looks like some shareholders thought, hang on a minute I'm seeing my holding dwindle here and I can get a piece of the action and stop my dilution with a better deal for ...
    19-Jul-2017
    fish lips
  • Re: Last Tranch from Bracknor?

    Bracknor waived the requirement to reduce the nominal: http://www.investegate.co.uk/advanced-oncotherapy--avo-/rns/update-on-bracknor-financing/201706051445381774H/ Now ...
    30-Jun-2017
    JakNife

Users' HoldingsMore

Users who hold Advanced Oncotherapy also hold..
LLOYDS GRP.21%
SIRIUS MINERALS14%
TESCO12%
ROYAL BANK SCOT12%
BT GROUP11%

Codes & Symbols

ISINGB00BD6SX109
SymbolsAVO, LSE:AVO, AVO.L, AVO:LN, LON:AVO, XLON:AVO